Cedar Knolls, NJ (PRWEB) March 30, 2006 –-
Xybion Medical Systems Corporation (Xybion), a developer and supplier of comprehensive preclinical data management systems, including its PATH/TOX SYSTEM™ Next Generation, announced today that Bayer HealthCare AG and Bayer CropScience AG, subgroups of Bayer AG have licensed PATH/TOX SYSTEM. The award of this contract contributed to Xybion’s most successful year; a total of eight new laboratories representing approximately 750 licensed users were added to Xybion’s user community.
“Bayer HealthCare AG and Bayer CropScience AG carried out a thorough market analysis in close cooperation on preclinical data management systems.” Gernot Goeller, Bayer HealthCare Project Lead said. “Both parties came to the same conclusion. The results convinced both our scientists and our lab technicians that the new PATH/TOX SYSTEM from Xybion Medical System will not only meet our needs but will also provide us with a range of important functionalities that where not available up to now. In addition, we look forward to having one single system in place world wide covering the needs for the safety assessment of new pharmaceuticals as well as agricultural products. A system covering the whole toxicology study process from test substance receipt to pathology”
“Bayer’s decision to license and deploy PATH/TOX SYSTEM world-wide demonstrates the marketplace’s continuing confidence in the high quality solutions provided by Xybion and in its world class customer service,” said David M. Neglia, President of Xybion. “We are delighted to see that our investment in development and our attention to quality is recognized by the market and considers Xybion a premier preclinical data management solution partner.”
PATH/TOX SYSTEM is a single solution that addresses all aspects of preclinical data acquisition, management and reporting. It is in production in 9 different countries throughout North America, Europe and Asia. Clients have the flexibility to license those components and options needed to support their study protocols and processes providing a client-centric custom solution. Xybion’s products are industry leaders and are used by some of the world’s largest and most prestigious pharmaceutical, chemical and contract research companies to assess compound safety while reducing the time to market for a new drug or chemical.
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare generated sales amounting to some 9.4 billion euros and employed 33,800 people worldwide in 2005.
The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The new Pharmaceuticals division was established on January 1, 2006, and comprises the former Biological Products and Pharmaceutical divisions. Pharmaceuticals now has three business units: Hematology/Cardiology, Oncology and Primary Care.
Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.